194 related articles for article (PubMed ID: 35896284)
21. Hypermutated tumours in the era of immunotherapy: The paradigm of personalised medicine.
Nebot-Bral L; Brandao D; Verlingue L; Rouleau E; Caron O; Despras E; El-Dakdouki Y; Champiat S; Aoufouchi S; Leary A; Marabelle A; Malka D; Chaput N; Kannouche PL
Eur J Cancer; 2017 Oct; 84():290-303. PubMed ID: 28846956
[TBL] [Abstract][Full Text] [Related]
22. The prevalence of mismatch repair deficiency in ovarian cancer: A systematic review and meta-analysis.
Atwal A; Snowsill T; Dandy MC; Krum T; Newton C; Evans DG; Crosbie EJ; Ryan NAJ
Int J Cancer; 2022 Nov; 151(9):1626-1639. PubMed ID: 35792468
[TBL] [Abstract][Full Text] [Related]
23. MEK1/2 inhibition transiently alters the tumor immune microenvironment to enhance immunotherapy efficacy against head and neck cancer.
Prasad M; Zorea J; Jagadeeshan S; Shnerb AB; Mathukkada S; Bouaoud J; Michon L; Novoplansky O; Badarni M; Cohen L; Yegodayev KM; Tzadok S; Rotblat B; Brezina L; Mock A; Karabajakian A; Fayette J; Cohen I; Cooks T; Allon I; Dimitstein O; Joshua B; Kong D; Voronov E; Scaltriti M; Carmi Y; Conde-Lopez C; Hess J; Kurth I; Morris LGT; Saintigny P; Elkabets M
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35292516
[TBL] [Abstract][Full Text] [Related]
24. CD122-directed interleukin-2 treatment mechanisms in bladder cancer differ from αPD-L1 and include tissue-selective γδ T cell activation.
Reyes RM; Deng Y; Zhang D; Ji N; Mukherjee N; Wheeler K; Gupta HB; Padron AS; Kancharla A; Zhang C; Garcia M; Kornepati AVR; Boyman O; Conejo-Garcia JR; Svatek RS; Curiel TJ
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33849925
[TBL] [Abstract][Full Text] [Related]
25. The Transcriptomic Landscape of Mismatch Repair-Deficient Intestinal Stem Cells.
Bommi PV; Bowen CM; Reyes-Uribe L; Wu W; Katayama H; Rocha P; Parra ER; Francisco-Cruz A; Ozcan Z; Tosti E; Willis JA; Wu H; Taggart MW; Burks JK; Lynch PM; Edelmann W; Scheet PA; Wistuba II; Sinha KM; Hanash SM; Vilar E
Cancer Res; 2021 May; 81(10):2760-2773. PubMed ID: 34003775
[TBL] [Abstract][Full Text] [Related]
26. BRD4 inhibition impairs DNA mismatch repair, induces mismatch repair mutation signatures and creates therapeutic vulnerability to immune checkpoint blockade in MMR-proficient tumors.
Fu Y; Yang B; Cui Y; Hu X; Li X; Lu F; Qin T; Zhang L; Hu Z; Guo E; Fan J; Xiao R; Li W; Qin X; Hu D; Peng W; Liu J; Wang B; Mills GB; Chen G; Sun C
J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37072347
[TBL] [Abstract][Full Text] [Related]
27. Clinicopathological features of 50 mismatch repair (MMR)-deficient endometrial carcinomas, tested by immunohistochemistry: A single institutional feasibility study, India.
Rekhi B; Menon S; Deodhar KK; Ghosh J; Chopra S; Maheshwari A
Ann Diagn Pathol; 2020 Aug; 47():151558. PubMed ID: 32619922
[TBL] [Abstract][Full Text] [Related]
28. Adding liposomal doxorubicin enhances the abscopal effect induced by radiation/αPD1 therapy depending on tumor cell mitochondrial DNA and cGAS/STING.
Wang L; Luo R; Onyshchenko K; Rao X; Wang M; Menz B; Gaedicke S; Grosu AL; Firat E; Niedermann G
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37640480
[TBL] [Abstract][Full Text] [Related]
29. Mismatch repair deficiency in metastatic prostate cancer: Response to PD-1 blockade and standard therapies.
Graham LS; Montgomery B; Cheng HH; Yu EY; Nelson PS; Pritchard C; Erickson S; Alva A; Schweizer MT
PLoS One; 2020; 15(5):e0233260. PubMed ID: 32453797
[TBL] [Abstract][Full Text] [Related]
30. Distinct Immunological Landscapes Characterize Inherited and Sporadic Mismatch Repair Deficient Endometrial Cancer.
Ramchander NC; Ryan NAJ; Walker TDJ; Harries L; Bolton J; Bosse T; Evans DG; Crosbie EJ
Front Immunol; 2019; 10():3023. PubMed ID: 31998307
[TBL] [Abstract][Full Text] [Related]
31. Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade.
Lee WS; Kim DS; Kim JH; Heo Y; Yang H; Go EJ; Kim JH; Lee SJ; Ahn BC; Yum JS; Chon HJ; Kim C
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764365
[TBL] [Abstract][Full Text] [Related]
32. Mismatch repair deficiency is not sufficient to elicit tumor immunogenicity.
Westcott PMK; Muyas F; Hauck H; Smith OC; Sacks NJ; Ely ZA; Jaeger AM; Rideout WM; Zhang D; Bhutkar A; Beytagh MC; Canner DA; Jaramillo GC; Bronson RT; Naranjo S; Jin A; Patten JJ; Cruz AM; Shanahan SL; Cortes-Ciriano I; Jacks T
Nat Genet; 2023 Oct; 55(10):1686-1695. PubMed ID: 37709863
[TBL] [Abstract][Full Text] [Related]
33. Unique Patterns of Heterogeneous Mismatch Repair Protein Expression in Colorectal Cancer Unveil Different Degrees of Tumor Mutational Burden and Distinct Tumor Microenvironment Features.
Berrino E; Aquilano MC; Valtorta E; Amodio V; Germano G; Gusmini M; Gizzi K; Fenocchio E; Sapino A; Marsoni S; Sartore-Bianchi A; Bardelli A; Siena S; Bonoldi E; Marchiò C
Mod Pathol; 2023 Feb; 36(2):100012. PubMed ID: 36853785
[TBL] [Abstract][Full Text] [Related]
34. PET imaging facilitates antibody screening for synergistic radioimmunotherapy with a
Ren J; Xu M; Chen J; Ding J; Wang P; Huo L; Li F; Liu Z
Theranostics; 2021; 11(1):304-315. PubMed ID: 33391476
[No Abstract] [Full Text] [Related]
35. Identification of Hypermutation and Defective Mismatch Repair in ctDNA from Metastatic Prostate Cancer.
Ritch E; Fu SYF; Herberts C; Wang G; Warner EW; Schönlau E; Taavitsainen S; Murtha AJ; Vandekerkhove G; Beja K; Loktionova Y; Khalaf D; Fazli L; Kushnir I; Ferrario C; Hotte S; Annala M; Chi KN; Wyatt AW
Clin Cancer Res; 2020 Mar; 26(5):1114-1125. PubMed ID: 31744831
[TBL] [Abstract][Full Text] [Related]
36. CD4 T Cell-Dependent Rejection of Beta-2 Microglobulin Null Mismatch Repair-Deficient Tumors.
Germano G; Lu S; Rospo G; Lamba S; Rousseau B; Fanelli S; Stenech D; Le DT; Hays J; Totaro MG; Amodio V; Chilà R; Mondino A; Diaz LA; Di Nicolantonio F; Bardelli A
Cancer Discov; 2021 Jul; 11(7):1844-1859. PubMed ID: 33653693
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of Nivolumab in Pediatric Cancers with High Mutation Burden and Mismatch Repair Deficiency.
Das A; Tabori U; Sambira Nahum LC; Collins NB; Deyell R; Dvir R; Faure-Conter C; Hassall TE; Minturn JE; Edwards M; Brookes E; Bianchi V; Levine A; Stone SC; Sudhaman S; Sanchez Ramirez S; Ercan AB; Stengs L; Chung J; Negm L; Getz G; Maruvka YE; Ertl-Wagner B; Ohashi PS; Pugh T; Hawkins C; Bouffet E; Morgenstern DA
Clin Cancer Res; 2023 Dec; 29(23):4770-4783. PubMed ID: 37126021
[TBL] [Abstract][Full Text] [Related]
38. Clinicopathological characteristics of endometrial carcinomas according to DNA mismatch repair protein status.
de Freitas D; Aguiar FN; Anton C; de Almeida DC; Bacchi CE; Carvalho JP; Carvalho FM
Heliyon; 2023 Jun; 9(6):e17495. PubMed ID: 37408903
[TBL] [Abstract][Full Text] [Related]
39. Clinical and genomic characterisation of mismatch repair deficient pancreatic adenocarcinoma.
Grant RC; Denroche R; Jang GH; Nowak KM; Zhang A; Borgida A; Holter S; Topham JT; Wilson J; Dodd A; Jang R; Prince R; Karasinska JM; Schaeffer DF; Wang Y; Zogopoulos G; Berry S; Simeone D; Renouf DJ; Notta F; O'Kane G; Knox J; Fischer S; Gallinger S
Gut; 2021 Oct; 70(10):1894-1903. PubMed ID: 32933947
[TBL] [Abstract][Full Text] [Related]
40. Mismatch repair deficiency and clinical implications in prostate cancer.
Graham LS; Schweizer MT
Prostate; 2022 Aug; 82 Suppl 1():S37-S44. PubMed ID: 35358351
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]